Advertisement
Endo Pharmaceuticals
Subscribe to Endo Pharmaceuticals

The Lead

Endo’s Purchase of Par Pharma Shakes up the Industry

May 21, 2015 11:03 am | News | Comments

US Pharma M&A activity has yet to show any signs of a slowdown after the $8.1bn exit of Par Pharma by TPG to Endo was announced on Monday. The US Pharma industry has seen 39 deals valued at US$ 77.3bn to-date, three more deals announced ...

Endo Acquires Portfolio of Branded and Generic Products

May 11, 2015 11:06 am | by Endo International | News | Comments

Endo International has acquired a broad portfolio of branded and generic injectable and...

Endo Tops Valeant's Offer for Salix

March 11, 2015 3:31 pm | by The Associated Press | News | Comments

Endo International is trying to lure fellow drugmaker Salix Pharmaceuticals with an offer Endo...

Endo to Divest American Medical Systems' Men's and Prostate Health Businesses to Boston Scientific

March 2, 2015 8:37 am | News | Comments

Endo International has entered into a definitive agreement with Boston Scientific, under which...

View Sample

FREE Email Newsletter

Endo Shakes Up Senior Management Team

January 9, 2015 8:37 am | News | Comments

Endo International has announced changes to its executive leadership and senior management team.  The changes are designed to support Endo's continued evolution into a leading global specialty healthcare company and accelerate growth both organically and through corporate development activities.

Endo Chief Legal Officer to Retire

January 6, 2015 8:02 am | News | Comments

Endo International  announced today that Caroline B. Manogue, Executive Vice President, Chief Legal Officer has advised the company that she intends to retire from the company on July 1, 2015.         

Endo Buys Struggling Auxilium for $2.6B to Augment Urology Franchise

October 10, 2014 9:36 am | News | Comments

Endo International’s $2.6 billion purchase of Auxilium Pharmaceuticals complements Endo’s urology and male health portfolio, and the company intends to leverage its resources to optimize and drive increased adoption of three key Auxilium drugs, according to an analyst with research and consulting firm GlobalData.

Advertisement

Endo to Buy Auxilium in Deal Worth $2.6B

October 9, 2014 7:46 am | by The Associated Press | News | Comments

Ireland's Endo International is buying Auxilium Pharmaceuticals Inc. in a sweetened cash-and-stock deal valued at $2.6 billion a few weeks after Auxilium rejected a lower bid for the company. Endo says it will pay $33.25 in cash and stock for each Auxilium share.

Auxilium Pharma Rejects Endo's Takeover Offer

September 22, 2014 8:02 am | News | Comments

Auxilium, based in Chesterbrook, Pennsylvania, had adopted a one-year "poison pill" shareholder rights plan last week. The drugmaker continues to support its plan to combine with Canadian eye drugmaker QLT Inc. in an all-stock deal.    

Endo Makes $1.4B Offer for Auxilium Pharma

September 16, 2014 5:45 pm | by The Associated Press | News | Comments

Endo International PLC says it is making an unsolicited offer for Auxilium Pharmaceuticals that values Auxilium at $28.10 per share. The deal is worth $1.41 billion in cash and stock, based on Auxilium's shares outstanding. Endo values the offer at $2.2 billion.

Big Cities Take Aim at Prescription Painkillers

September 16, 2014 2:25 pm | by MATTHEW PERRONE, AP Health Writer | News | Comments

Some of the nation's largest cities are ratcheting up their criticism of prescription painkillers, blaming the industry for a wave of addiction and overdoses that have ravaged their communities and busted local budgets.      

FDA: Little Evidence to Support Testosterone Drugs

September 3, 2014 3:30 pm | by MATTHEW PERRONE, AP Health Writer | News | Comments

The Food and Drug Administration says there is little evidence that testosterone-boosting drugs taken by millions of American men are beneficial, though the agency is also unconvinced by studies suggesting the hormone carries serious risks.  

Advertisement

Endo and BioDelivery Sciences Announce Phase III Results for BEMA buprenorphine in Opioid-Experienced Patients with Chronic Pain

July 7, 2014 8:10 am | News | Comments

BEMA buprenorphine is being developed for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate in both patients who are opioid naive and opioid experienced.

Endo to Acquire DAVA Pharmaceuticals

June 25, 2014 9:17 am | News | Comments

Endo International has reached a definitive agreement to acquire DAVA Pharmaceuticals, Inc., a privately-held company specializing in marketed, pre-launch and pipeline generic pharmaceuticals, for $575 million in cash, with additional cash consideration of up to $25 million contingent on the achievement of certain sales milestones. 

Asana BioSciences, an Amneal Alliance Company, Acquires Branded Drug Discovery Platform from Endo International

June 3, 2014 8:12 am | News | Comments

Asana BioSciences, an independent member of the Amneal Alliance of Companies, has acquired the early stage branded pharmaceutical discovery platform of Endo Pharmaceuticals, a subsidiary of Endo International plc.      

California Counties Sue Over Painkiller Marketing

May 22, 2014 3:18 pm | by PAUL ELIAS, Associated Press | News | Comments

Two California counties have filed a lawsuit accusing five drug companies of waging a campaign of deception to boost the sales of painkillers behind the nation's prescription drug addiction problem.         

Endo to Acquire Specialty Pharmaceuticals Company Somar

April 29, 2014 8:39 am | News | Comments

Endo International has entered into a definitive agreement under which Endo will acquire Grupo Farmaceutico Somar, a privately-owned specialty pharmaceuticals company based in Mexico City, Mexico, for cash consideration.     

Advertisement

Endo Appoints New Chief Scientific Officer and Global Head of R&D and Quality

March 7, 2014 8:04 am | News | Comments

Endo International has appointed Susan Hall, Ph.D. as executive vice president, chief scientific officer and global head of research & development and quality, effective March 10, 2014.           

FDA Approves Endo U.S. Testosterone Replacement Therapy

March 6, 2014 8:13 am | News | Comments

Endo Pharmaceuticals has received FDA approval of AVEED (testosterone undecanoate) injection for the treatment of adult men with hypogonadism (commonly known as Low-T) that is associated with a deficiency or absence of the male hormone testosterone.

Endo Shareholders Approve Acquisition of Paladin Labs

February 26, 2014 3:51 pm | News | Comments

Endo Health Solutions Inc. has announced that, at the shareholder meeting held today, proposals related to Endo's proposed acquisition of Paladin Labs Inc. were approved by Endo's shareholders.         

Endo Health to Pay $192.7M in Government Settlement

February 21, 2014 3:36 pm | by The Associated Press | News | Comments

Endo Health will pay almost $193 million to resolve claims that it improperly marketed the shingles treatment Lidoderm for unapproved uses like treating lower back pain.              

Endo Completes Acquisition of Specialty Generics Company Boca Pharmacal

February 3, 2014 8:09 am | News | Comments

Endo Health Solutions today announced that its Qualitest subsidiary has completed the acquisition of privately held Boca Pharmacal, a specialty pharmaceutical company, for approximately $225 million in cash.       

Endo Health Sells HealthTronics for up to $130M

January 9, 2014 1:29 pm | News | Comments

Endo Health Solutions said Thursday it will sell its HealthTronics urology unit for up to $130 million as it streamlines its business. Investment firm Altaris Capital Partners will pay $85 million upfront for HealthTronics, and Endo could get an additional $45 million based on the performance of the business.

Endo to Acquire Specialty Pharmaceutical Company NuPathe

December 16, 2013 8:27 am | News | Comments

Endo Health Solutions will acquire NuPathe Inc. for $2.85 per share in cash, or approximately $105 million.  In addition to the upfront cash payment, NuPathe shareholders will receive rights to receive additional cash payments of up to $3.15 per share if specified net sales of NuPathe's migraine treatment ZECUITY are achieved over time.

Endo Health to Buy Paladin Labs for $1.5B

November 5, 2013 8:07 am | News | Comments

Endo Health is buying the Canadian specialty drug maker Paladin Labs for about $1.5 billion, and both will then be folded into a newly-formed Irish holding company.             

Endo Health Names Upadhyay as its Next CFO

September 9, 2013 2:59 pm | by The Associated Press | News | Comments

Endo Health Solutions said Monday that former Becton Dickinson executive Suketu Upadhyay will join the company as chief financial officer Sept. 23. Upadhyay has been Becton Dickinson & Co.'s chief accounting officer and was interim CFO from November 2012 to July 2013.

Endo Health Says FDA Accepts Aveed Application

September 5, 2013 10:56 am | by The Associated Press | News | Comments

Endo Health Solutions said Thursday that regulators accepted for review new data for its long-acting testosterone injection Aveed and will make a ruling on the drug by Feb. 28. The Food and Drug Administration asked Endo for more information in May. Endo said the FDA was concerned about risks and...

Endo to Acquire Boca Pharmacal for $225M

August 28, 2013 9:16 am | News | Comments

Endo Health Solutions announced that its Qualitest subsidiary has reached a definitive agreement to acquire privately held Boca Pharmacal, a specialty generics company, for $225 million in cash.  The transaction is expected to enhance the growth platform and pipeline for Endo's Qualitest business and is consistent with Endo's strategic transformation into a leading specialty healthcare company. 

Endo Second Quarter Net Income Rises as Charges Decrease

August 6, 2013 3:11 pm | by The Associated Press | News | Comments

Endo Health Solutions Inc. said Tuesday its net income rose in the second quarter despite a series of charges related to its planned shift in business strategy and an allowance for potential lawsuits. The company also raised its full-year guidance, but shares slipped in afternoon trading In June...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading